Metabolic and Infectious Diseases in La Réunion (the REUNION Population-based Study)
NCT ID: NCT05400824
Last Updated: 2022-07-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2000 participants
OBSERVATIONAL
2022-05-01
2024-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Known or suspected risk factor for these diseases will also be assessed, such as microbiota, cognitive impairement, social inequalities, and genetics.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinico-biological Collection of Subjects With Hyper Lipoprotein a in Reunion Island
NCT04310917
Epidemiology of Gout in French Polynesia
NCT04812886
Metagenomics and Integrative Systems Medicine of Cardiometabolic Diseases
NCT02059538
Genetic Factors and Immunological Determinism of Persistent Consequences of Chikungunya
NCT03690648
Population Genomic Diversity of France
NCT04183023
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
general population
Observational study of 2000 adult men and women from the general population who will benefit from a free extensive health check up in La Reunion
Blood, DNA, feces, urine, hair and skin microbiota collection
See above
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood, DNA, feces, urine, hair and skin microbiota collection
See above
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* given consent for genetic analysis,
* written consent for participating in the study
Exclusion Criteria
18 Years
67 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maxime COURNOT, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Institut National de la Santé Et de la Recherche Médicale, France
Olivier MEILHAC, PhD
Role: STUDY_DIRECTOR
Institut National de la Santé Et de la Recherche Médicale, France
Patrick MAVINGUI, PhD
Role: STUDY_DIRECTOR
Institut National de la Santé Et de la Recherche Médicale, France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Universitaire de La Réunion
La Réunion, Saint-Pierre, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
official website of the French National Institute for Health and Medical Research
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020A0209435
Identifier Type: REGISTRY
Identifier Source: secondary_id
C19-68
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.